BBOT to Participate in Upcoming December Investor Healthcare Conferences
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) said members of its leadership team will present at two investor healthcare conferences in early December 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) said members of its leadership team will present at two investor healthcare conferences in early December 2025.
Presentation schedule: Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 2:00 PM ET, and Evercore 8th Annual Healthcare Conference on Wednesday, December 3, 2025 at 9:35 AM ET. Live webcasts will be available on the company's Events page, with replays accessible for at least 90 days after each event.
Details
News Market Reaction – BBOT
On Nov 19, the first trading day after this news, BBOT closed 5.93% below the previous close.
Data tracked by StockTitan Argus for the Nov 19 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in December.
Details of the company’s participation are as follows:
- Piper Sandler 37th Annual Healthcare Conference
Presentation: Tuesday, December 2, at 2:00 p.m. ET
- 8th Annual Evercore Healthcare Conference
Presentation: Wednesday, December 3, at 9:35 a.m. ET
Live webcasts of the presentations will be accessible on the “Events” page of the BBOT website at https://investors.bbotx.com/news-events/events. Replays of the webcasts will be available for at least 90 days following the event.
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact:
Heather Armstrong
BBOT
Heather.Armstrong@bbotx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.